ALX Oncology Holdings Inc. (ALXO)
After hours:
| Previous Close | 16.95 |
| Open | 17.50 |
| Bid | 16.15 x 200 |
| Ask | 16.24 x 400 |
| Day's Range | 15.94 - 17.50 |
| 52 Week Range | 3.94 - 17.83 |
| Volume | |
| Avg. Volume | 528,945 |
| Market Cap | 818.585M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.74 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.15 |
- GuruFocus.com
ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
Consistent with Analyst Projections Amidst Clinical Advancements
GlobeNewswireALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We entered the quarter with a great deal of momentum having achieved a key validating development milestone for our platform asset evorpacept in Q4 2023 b
- GlobeNewswire
ALX Oncology Appoints Allison Dillon as Chief Business Officer
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX
